Bret Stephens’ Pharmapologetics
Now, when the demand for both innovation and access is high, it’s time to think outside the box and reevaluate the relationship between pharmaceutical drugs and the patent system. Perhaps a prize system is in order, or maybe a formal guarantee from firms receiving BARDA grants that the drugs will not be patented.Featured Publications
Low-Energy Fridays: Would IRA repeal end clean energy growth?
The Competition Solution to the Primary Problem
Emission Benefits of Permitting Reform: A Solution for America’s Energy Future
Real Insights: Trust, Freedom, and the Future—A Conversation with Lenore Skenazy
The Economic Case for Clean Slate Policy
The Google Search Case: A Remedy Searching for an Ailment